IDT Australia Limited (AU:IDT) has released an update.
IDT Australia Limited has reported a 70% increase in quarterly revenue to $5.2 million, marking a two-year high as it continues its strategic transformation. The pharmaceutical manufacturer attributes the growth to a significant rise in return business and new contracts worth $6.8 million, driven by high customer satisfaction and demand for advanced therapies. The company remains optimistic about exceeding the previous year’s revenue, supported by a strong pipeline of proposals.
For further insights into AU:IDT stock, check out TipRanks’ Stock Analysis page.